Hollings Renton
CIK 1187333 · President and CEO · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONXX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANAB | Director | 10,995 | $48.63 | $534.7K | -$1.62M | 20 | 2026-10-02 |
| ZYME | Director | — | $28.13 | — | $0 | 5 | 2023-12-08 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | -$875.4K | 14 | 2020-07-02 |
| CEPHEID (CPHD) Delisted | Director | 0 | — | — | -$4.29M | 23 | 2016-11-07 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | — | — | — | $0 | 3 | 2015-10-02 |
| RIGL | Director | — | $48.48 | — | $0 | 7 | 2013-05-28 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 4 | 2012-06-18 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | President and CEO | 232,490 | — | — | -$8.55M | 9 | 2008-02-26 |
Recent Filings · Page 5 of 10
91 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-20 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2016-04-28 | CEPHEID (CPHD) Delisted | Grant (A) | +1,800 | $0 | EDGAR |
| 2015-10-02 | KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Disp (D) | — | $0 | EDGAR |
| 2015-06-17 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-04 | KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-12 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Mixed | — | -$329.5K | EDGAR |
| 2015-04-28 | CEPHEID (CPHD) Delisted | Grant (A) | +1,800 | $0 | EDGAR |
| 2015-04-23 | CEPHEID (CPHD) Delisted | Exer (M) | +1,800 | $0 | EDGAR |
| 2015-02-26 | CEPHEID (CPHD) Delisted | Mixed | — | -$242.9K | EDGAR |
| 2015-01-05 | KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.